Medicago's COVID-19 vaccine triggers immune response in early-stage trial

The company, which is backed by Mitsubishi Tanabe Pharma and tobacco giant Philip Morris, said it planned to move into mid-to-late-stage trials with a lower dose version of its vaccine, along with the GSK adjuvant. “What we’re most encouraged with is that we are able to go with the lowest dose for our phase 2/3 trials,” Medicago’s Chief Executive Officer Bruce Clark told Reuters. Trials from rival coronavirus vaccine developers have generally shown that lower doses produce less side effects. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.